DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

ABT·Abbott Laboratories

$.
-. (-.%)
After Hours
High
$88.24
Open
$86.83
Market Cap
152.25B
52W High
$139.06
Low
$85.81
P. Close
$86.66
P/E
24.26
52W Low
$81.97
Fwd P/E
14.32
Mean Target
$118.64
Technical Score (1D)
14
SELL
News Sentiment
65
BULLISH
Abbott Laboratories (ABT) saw its stock price impacted by headwinds in its nutrition business segment. This segment's performance is a key driver of the company's overall financial results, and investors are now scrutinizing the potential effects on future earnings and the company's strategic response to these challenges.
Earnings Summary
Abbott Laboratories is a global healthcare company focused on the discovery, development, and commercialization of a diverse portfolio of health products across established pharmaceuticals, diagnostics, nutritionals, and medical devices. Its diagnostics segment provides laboratory systems and rapid testing solutions, while its medical devices segment develops products for cardiovascular health, diabetes care, and neuromodulation. In the most recent two reported quarters, Q1 2026 saw actual EPS of $1.15 on revenue of $11.164 billion, beating the EPS estimate of $1.146 but missing the revenue estimate of $10.997 billion. This followed Q4 2025, where the company reported actual EPS of $1.50 on revenue of $11.459 billion, missing the EPS estimate of $1.511 but also missing the revenue estimate of $11.924 billion. The trend shows a slight deceleration in EPS performance from Q4 2025 into Q1 2026, with revenue also missing estimates in both periods. Historically, Abbott Laboratories has demonstrated a pattern of narrowly beating or meeting EPS estimates in recent quarters, with Q1 2026 and Q4 2025 being exceptions where EPS was met or slightly missed, respectively, and revenue estimates were missed in both. Recent news highlights FDA clearance and CE Mark for its AI-powered Ultreon 3.0 Software for cardiac procedures and positive clinical data for its PFA and CSP portfolios. The company is also identified as a key player in the growing breath analyzer market and the GLP-1 hydration products market. However, Polen Capital's Focus Growth Strategy divested its stake in Abbott. Investors should watch for the adoption and impact of the Ultreon 3.0 software, continued innovation in its cardiovascular and diagnostics segments, and the performance of its nutritional and diagnostics divisions, particularly in light of slower recent growth, in the upcoming quarters.

EPS

EstBeatMiss
$1.01$1.15$1.29$1.43$1.58Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.28 - -
Q1'26$1.15$1.15+0.3%
Q4'25$1.51$1.50-0.8%
Q3'25$1.30$1.30+0.0%
Q2'25$1.26$1.26+0.3%
Q1'25$1.07$1.09+1.7%

Revenue

EstBeatMiss
$10.0B$10.8B$11.5B$12.3B$13.0BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$12.7B - -
Q1'26$11.0B$11.2B+1.5%
Q4'25$11.9B$11.5B-3.9%
Q3'25 - $11.4B -
Q2'25 - $11.1B -
Q1'25 - $10.4B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ABT Stock Snapshot

ABT is currently trading at $86.81, giving Abbott Laboratories a market cap of 152.25B and a P/E ratio of 24.3. Today's range spans $85.81–$88.24, with shares opening at $86.83 and moving up $0.15 (0.2%) from the prior close. DailyIQ's technical score sits at 14/100 (SELL) with a news sentiment reading of 65/100.

Over the past year ABT has traded between $81.97 and $139.06 - the current price is +5.9% off the 52-week low and -37.6% from the high. 37 analysts cover the stock with a Buy consensus and a mean 12-month target of $118.64 (range $92.00–$143.00), implying upside of +36.7%.

When ABT shows a SELL (14/100) alongside bullish sentiment (65/100), the right posture for most Healthcare investors is reduced exposure rather than conviction buying. Price: $86.81 (near 52-week lows). (P/E: 24.3) At 152.25B in capitalization, the structural support levels within the $81.97–$139.06 annual range are where the setup becomes reassessable - not before.

When a large-cap Healthcare name with 152.25B in capitalization prints a SELL signal (14/100) alongside bullish news sentiment (65/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $86.81 (near 52-week lows in the $81.97–$139.06 range), the structural support levels are where that sponsorship question gets answered.